Wirkung carcinostatischer äthylenimin-verbindungen auf den DPN-gehalt therapieresistener tumoren

Preliminary experiments with the ascites form of the relatively
therapeutic-resistant DS-tumour demonstrated that the decrease in
DPN content and the inhibition of glycolysis in the neoplastic
cells under the influence of ethylenimine compounds were delayed,
in comparison with the rapid changes observed in Ehrlich-ascites
carcinomas. Extending these observations, the therapeutic effect of
carcinostatic ethylenimine compounds was studied in rats bearing
solid forms of either the Jensen sarcoma or the
therapeutic-resistant DS-tumour. During the course of the
experiments the DPN content of the tumours was followed. In the
Jensen sarcoma the DPN content decreased sharply as early as the
first day following administration of the carcinostatic, while the
DS-tumour, in contrast, showed no clear change during the first six
days. A cure was obtained in nine out of thirteen cases of the
Jensen-sarcoma rats, while no cure was observed in six
DS-tumour-bearing rats. These experiments further support our
hypothesis, that carcinostatic ethylenimine compounds are
therapeutically effective though they depress the DPN content in
the tumour.